Baxter International Inc. - Form 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Baxter International Inc., a global healthcare company operating in Medication Delivery, BioScience, and Renal segments. The report covers the quarterly and nine-month periods ended September 30, 2002.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2002 | 9 Months Ended Sep 30, 2002 | 9 Months Ended Sep 30, 2001 |
|---|---|---|---|
| Net Sales | $2,102 | $6,074 | $5,527 |
| Net Income | $316 | $769 | $687 |
| Earnings Per Share (Diluted) | $0.51 | $1.24 | $1.13 |
| Cash Flow from Operations | N/A | $417 | $361 |
| Total Debt (Short + Long Term) | $1137 | $3,087 | $2,687 |
| Cash and Equivalents | $278 | $278 | $470 |
| Gross Margin | 45.0% | 45.3% | 44.4% |
Note: Total Debt calculated as Short-term debt ($152M) + Current maturities ($50M) + Long-term debt ($2,935M) for 2002.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% for the quarter and 10% year-to-date compared to 2001. Excluding currency fluctuations, sales growth was 9% (quarter) and 11% (year-to-date).
- Profitability: Net income rose 16% for the quarter and 12% year-to-date. Diluted EPS increased 13% for the quarter and 10% year-to-date.
- Segment Performance:
- Medication Delivery: Sales up 16% (quarter) and 14% (YTD), driven by oncology and anesthesia products.
- BioScience: Sales up 14% (quarter) and 13% (YTD), led by strong demand for Recombinate (hemophilia treatment).
- Renal: Sales declined 2% (quarter) and were flat (YTD) due to currency headwinds and decreased hemodialysis sales outside the U.S.
- Unusual Items:
- IPR&D Charge: A $51 million charge was recorded in Q2 2002 related to the acquisition of Fusion Medical Technologies.
- Impairment: A $70 million charge was recorded in Q2 2002 for the impairment of two non-strategic investments.
- Accounting Change: Goodwill is no longer amortized under SFAS No. 142 (effective Jan 1, 2002), eliminating a prior expense line item.
Guidance, Outlook, and Risks
- Outlook: Management revised full-year 2002 sales growth expectations to "low-double digits" (up from "low-teens" in the 2001 report). EPS growth is expected to be in the mid-teens excluding non-recurring charges.
- Cash Flow: Operational cash flow was negative $146 million for the first nine months due to high capital expenditures ($578M) and working capital increases. Management expects significant cash generation in the fourth quarter due to seasonal patterns.
- Acquisitions:
- Completed: Fusion Medical Technologies (May 2002) for $161M (stock).
- Pending: Acquisition of ESI Lederle (Wyeth) for approx. $305M, expected to close Q4 2002.
- Risks and Contingencies:
- Legal Proceedings: Significant ongoing litigation regarding mammary implants (Heyer-Schulte), plasma-based therapies (HIV/Hepatitis C claims), and the A, AF, and AX series dialyzers (patient deaths in Croatia/Spain). Reserves are maintained, but additional losses are possible.
- Supply Chain: BioScience segment faces potential supply constraints for Recombinate due to third-party manufacturing yields, which may impact Q4 2002 and Q1 2003 sales.
- Market Risk: Significant exposure to currency fluctuations and equity forward agreements (approx. 35 million shares outstanding).
Investor Verification Checklist
- Legal Reserves: Verify the adequacy of reserves for the dialyzer recall and mammary implant litigation, as management notes potential for additional losses exceeding current reserves.
- Supply Constraints: Monitor Q4 2002 sales of Recombinate to confirm if the anticipated supply shortage materializes.
- Acquisition Integration: Track the closing and integration of the ESI Lederle acquisition and the associated IPR&D charges expected in Q4.
- Cash Flow Seasonality: Confirm Q4 operational cash flow generation to offset the negative operational cash flow of the first nine months.
- Equity Forwards: Review the status of the 35 million share equity forward agreements and the company's strategy to exit these positions.